552 related articles for article (PubMed ID: 12145848)
1. [Recent notions on intestinal cancerogenesis, their implications in genetic risk screening and preventive action of non-steroid anti-inflammatory agents].
Couturier D
Bull Acad Natl Med; 2002; 186(2):421-43; discussion 443-5. PubMed ID: 12145848
[TBL] [Abstract][Full Text] [Related]
2. Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
Johnson V; Lipton LR; Cummings C; Eftekhar Sadat AT; Izatt L; Hodgson SV; Talbot IC; Thomas HJ; Silver AJ; Tomlinson IP
J Med Genet; 2005 Oct; 42(10):756-62. PubMed ID: 15788729
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes.
Losi L; Di Gregorio C; Pedroni M; Ponti G; Roncucci L; Scarselli A; Genuardi M; Baglioni S; Marino M; Rossi G; Benatti P; Maffei S; Menigatti M; Roncari B; Ponz de Leon M
Am J Gastroenterol; 2005 Oct; 100(10):2280-7. PubMed ID: 16181381
[TBL] [Abstract][Full Text] [Related]
4. Hereditary colorectal cancer syndromes.
Strate LL; Syngal S
Cancer Causes Control; 2005 Apr; 16(3):201-13. PubMed ID: 15947872
[TBL] [Abstract][Full Text] [Related]
5. A search for germline APC mutations in early onset colorectal cancer or familial colorectal cancer with normal DNA mismatch repair.
Boardman LA; Schmidt S; Lindor NM; Burgart LJ; Cunningham JM; Price-Troska T; Snow K; Ahlquist DA; Thibodeau SN
Genes Chromosomes Cancer; 2001 Feb; 30(2):181-6. PubMed ID: 11135435
[TBL] [Abstract][Full Text] [Related]
6. Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome.
Johnson V; Volikos E; Halford SE; Eftekhar Sadat ET; Popat S; Talbot I; Truninger K; Martin J; Jass J; Houlston R; Atkin W; Tomlinson IP; Silver AR
Gut; 2005 Feb; 54(2):264-7. PubMed ID: 15647192
[TBL] [Abstract][Full Text] [Related]
7. [Familial adenomatous polyposis syndrome (FAP): pathogenesis and molecular mechanisms].
Friedrich A; Kullmann F
Med Klin (Munich); 2003 Dec; 98(12):776-82. PubMed ID: 14685680
[TBL] [Abstract][Full Text] [Related]
8. [Molecular etiology of colorectal carcinogenesis, clinical manifestations and therapy].
Jacobasch G; Jacobasch KH
Z Arztl Fortbild Qualitatssich; 1997 Mar; 91(2):125-33. PubMed ID: 9244653
[TBL] [Abstract][Full Text] [Related]
9. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli.
Bläker H; Sutter C; Kadmon M; Otto HF; Von Knebel-Doeberitz M; Gebert J; Helmke BM
Genes Chromosomes Cancer; 2004 Oct; 41(2):93-8. PubMed ID: 15287021
[TBL] [Abstract][Full Text] [Related]
10. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer.
Miyaki M; Iijima T; Kimura J; Yasuno M; Mori T; Hayashi Y; Koike M; Shitara N; Iwama T; Kuroki T
Cancer Res; 1999 Sep; 59(18):4506-9. PubMed ID: 10493496
[TBL] [Abstract][Full Text] [Related]
11. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
12. Cohorts with familial disposition for colon cancers in chemoprevention trials.
Burt RW
J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
[TBL] [Abstract][Full Text] [Related]
13. [Genetics of colorectal cancer. II. Hereditary background of sporadic and familial colorectal cancer].
Menko FH; Griffioen G; Wijnen JT; Tops CM; Fodde R; Vasen HF
Ned Tijdschr Geneeskd; 1999 Jun; 143(23):1207-11. PubMed ID: 10389535
[TBL] [Abstract][Full Text] [Related]
14. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors.
Aaltonen L; Johns L; Järvinen H; Mecklin JP; Houlston R
Clin Cancer Res; 2007 Jan; 13(1):356-61. PubMed ID: 17200375
[TBL] [Abstract][Full Text] [Related]
15. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
Mathers JC; Mickleburgh I; Chapman PC; Bishop DT; Burn J;
Proc Nutr Soc; 2003 Feb; 62(1):51-7. PubMed ID: 12740057
[TBL] [Abstract][Full Text] [Related]
16. Multistep carcinogenesis in colorectal cancers.
Takami K; Yana I; Kurahashi H; Nishisho I
Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():190-6. PubMed ID: 8629105
[TBL] [Abstract][Full Text] [Related]
17. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
18. [Familial cancer: recent advances].
Baba S
Gan To Kagaku Ryoho; 1999 May; 26(6):735-43. PubMed ID: 10410140
[TBL] [Abstract][Full Text] [Related]
19. Chronic inflammatory bowel disease and cancer.
Pohl C; Hombach A; Kruis W
Hepatogastroenterology; 2000; 47(31):57-70. PubMed ID: 10690586
[TBL] [Abstract][Full Text] [Related]
20. Mouse models for colorectal cancer.
Heyer J; Yang K; Lipkin M; Edelmann W; Kucherlapati R
Oncogene; 1999 Sep; 18(38):5325-33. PubMed ID: 10498885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
